Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 study

Bergh, Florian Then; Singer, BA; Drulović, Jelena S.; Bidollari, I.; Chen, Hailu; Englishby, R.; Hanna, Jerome; Kandinov, Boris; Lopez-Bresnahan, Maria; Leigh-Pemberton, Richard; Miller, Catherine; Mokliatchouk, O.; Shafer, SJ

Rezultati

eNauka > Rezultati > Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 study

Naziv :	Diroximel fumarate (DRF) in patients with relapsing-remitting multiple sclerosis: interim safety and efficacy results from the Phase 3 EVOLVE-MS-1 study
Autori:	Bergh, Florian Then; Singer, BA; Drulović, Jelena S. ; Bidollari, I.; Chen, Hailu; Englishby, R.; Hanna, Jerome; Kandinov, Boris; Lopez-Bresnahan, Maria; Leigh-Pemberton, Richard; Miller, Catherine; Mokliatchouk, O.; Shafer, SJ;
Godina:	2019
Publikacija:	Multiple sclerosis journal (35th Congress of the European-Committee-for-Treatment-and-Research-in-Multiple-Sclerosis (ECTRIMS 2019), Sep 11-13, 2019, Stockholm, Sweden)
ISSN:	1352-4585 Multiple Sclerosis Pretraži identifikator
Izdavač:	London : SAGE Publications
Tip rezultata:	Konferencijski rad
Kolacija:	vol. 25 br. Suppl 2 str. 861-862
WoS-ID:	000485303103349
URI:	https://enauka.gov.rs/handle/123456789/827905
URL:	https://journals.sagepub.com/doi/full/10.1177/1352458519872904
Projekat:	Biogen/Alkermes Biogen (Cambridge, MA, USA) Alkermes (Waltham, MA, USA) Biogen
Izvor metapodataka:	(Preuzeto iz Nasi u WoS)
M-kategorija:	Mp kategorija će biti prikazana naknadno.

Pronađi DOI

Pronalaženje DOI u servisu CrossRef-u na osnovu meta-podataka u zapisu. Prikazaće se DOI (i metapodaci) čiji se podaci najviše poklapaju. OPREZ - to ne mora biti ta publikacija.

Google Scholar^TM

Rezultati na eNauka su zaštićeni autorskim pravima i sva prava su zadržana, osim ako nije drugačije naznačeno.